Protagonist Therapeutics, Inc.

NASDAQ (USD): Protagonist Therapeutics, Inc. (PTGX)

Last Price

46.46

Today's Change

+4.81 (11.54%)

Day's Change

42.44 - 47.50

Trading Volume

1,271,683

Overview

Market Cap

2 Billion

Shares Outstanding

59 Million

Avg Volume

653,339

Avg Price (50 Days)

45.26

Avg Price (200 Days)

35.79

PE Ratio

16.96

EPS

2.74

Earnings Announcement

25-Feb-2025

Previous Close

41.65

Open

43.30

Day's Range

42.44 - 47.5

Year Range

16.8 - 48.89

Trading Volume

1,271,683

Price Change Highlight

1 Day Change

11.55%

5 Day Change

13.37%

1 Month Change

-0.28%

3 Month Change

11.47%

6 Month Change

52.13%

Ytd Change

98.38%

1 Year Change

169.65%

3 Year Change

33.93%

5 Year Change

457.07%

10 Year Change

297.09%

Max Change

297.09%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment